Global Liver Disease Treatment Market 2017-2021

  • ID: 4335604
  • Report
  • Region: Global
  • 98 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Johnson and Johnson
  • Merck
  • Novartis
  • MORE
About Liver Disease Treatment

Liver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal.

Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries.

The analysts forecast the global liver disease treatment market to grow at a CAGR of 11.01% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global liver disease treatment market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs in liver disease treatment market.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Liver Disease Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
Other prominent vendors
  • Bristol-Myers Squibb
  • Johnson and Johnson
  • Novartis
  • Salix Pharmaceuticals
  • Vertex Pharmaceuticals
Market drivers
  • Increase in alcohol-related liver disease
  • For a full, detailed list, view the full report
Market challenges
  • Side-effects of liver disease treatment drugs
  • For a full, detailed list, view the full report
Market trends
  • Rise in awareness
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Johnson and Johnson
  • Merck
  • Novartis
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Drug class segmentation
  • Global liver disease treatment market by anti-viral drugs
  • Global liver disease treatment market by corticosteroids
  • Global liver disease treatment market by other drugs
  • Global liver disease treatment market by vaccines
PART 08: Market segmentation by disease type
  • ARLD
  • NAFLD
  • Hepatitis
  • PBC
  • Hemochromatosis
PART 09: Geographical segmentation
  • Liver disease treatment market in Americas
  • Liver disease treatment market in EMEA
  • Liver disease treatment market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Rise in awareness
  • Increase in R&D activities for liver cirrhosis medication
  • Increasing collaborations and M&A
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Functions of liver
Exhibit 02: Types of liver diseases
Exhibit 03: Global liver disease treatment market
Exhibit 04: Global liver disease treatment market 2016-2021 ($ billions)
Exhibit 05: Opportunity analysis of global liver disease drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline summary based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global liver disease market by drug class
Exhibit 10: Global liver disease treatment market by drug class 2016 and 2021
Exhibit 11: Global liver disease treatment market by anti-viral drugs 2016-2021 ($ billions)
Exhibit 12: HIV treatment regimen approved by FDA
Exhibit 13: Global liver disease treatment market by corticosteroids 2016-2021 ($ billions)
Exhibit 14: Global liver disease treatment market by other drugs 2016-2021 ($ billions)
Exhibit 15: Global liver disease treatment market by vaccines 2016-2021 ($ billions)
Exhibit 16: Vaccination coverage for birth dose of hepatitis B vaccine in various regions 2013
Exhibit 17: Vaccination coverage for three doses of hepatitis B vaccine in various regions 2013
Exhibit 18: Global liver disease treatment market by disease type
Exhibit 19: Stages of ARLD
Exhibit 20: Deaths due to ARLD in US 2014
Exhibit 21: Stages of NAFLD
Exhibit 22: Types of hepatitis
Exhibit 23: Mode of transmission and incubation period of different types of hepatitis
Exhibit 24: Hepatitis A: Key marketed drugs
Exhibit 25: Hepatitis B: Key marketed drugs
Exhibit 26: Hepatitis C: Key marketed drugs
Exhibit 27: Medications for symptoms of PBC
Exhibit 28: Global liver disease treatment market by geography 2016 and 2021
Exhibit 29: Global liver disease treatment market by geography 2016-2021 ($ billions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Liver disease treatment market in Americas 2016-2021 ($ billions)
Exhibit 32: Factors contributing to liver cancer in US
Exhibit 33: Hepatitis infection scenario in US, 2015-2016
Exhibit 34: Market scenario in EMEA
Exhibit 35: Liver disease treatment market in EMEA 2016-2021 ($ billions)
Exhibit 36: Market scenario in APAC
Exhibit 37: Liver disease treatment market in APAC 2016-2021 ($ billions)
Exhibit 38: Top Asian countries in terms of population with diabetes
Exhibit 39: Countries with large populations without adequate sanitation 2014
Exhibit 40: Effects of lifestyle diseases on liver
Exhibit 41: Competitive structure analysis of global liver disease treatment market 2016
Exhibit 42: Strategic success factors of companies in global liver disease treatment market
Exhibit 43: F. Hoffmann-la Roche: Key highlights
Exhibit 44: F. Hoffmann-la Roche: Strength assessment
Exhibit 45: F. Hoffmann-la Roche: Strategy assessment
Exhibit 46: F. Hoffmann-la Roche: Opportunity assessment
Exhibit 47: Gilead: Key highlights
Exhibit 48: Gilead: Strength assessment
Exhibit 49: Gilead: Strategy assessment
Exhibit 50: Gilead: Opportunity assessment
Exhibit 51: GlaxoSmithKline: Key highlights
Exhibit 52: GlaxoSmithKline: Strength assessment
Exhibit 53: GlaxoSmithKline: Strategy assessment
Exhibit 54: GlaxoSmithKline: Opportunity assessment
Exhibit 55: Merck: Key highlights
Exhibit 56: Merck: Strength assessment
Exhibit 57: Merck: Strategy assessment
Exhibit 58: Merck: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Johnson and Johnson
  • Merck
  • Novartis
  • MORE
New Report Released: - Global Liver Disease Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global liver disease treatment market: F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, and Merck.

Other Prominent Vendors in the market are: ristol-Myers Squibb, Johnson and Johnson, Novartis, Salix Pharmaceuticals, and Vertex Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Rise in awareness. Early detection is crucial in reducing the progression of liver diseases. For instance, diagnosis of hepatitis B and C at an initial stage can reduce or prevent the extent of liver damage. Government and non-governmental organizations organize summits, awareness seminars, campaigns, and fundraising events to raise awareness about both the disease and the therapeutic measures available.

For instance, the US celebrates May 19 as Hepatitis Testing Day and has deemed the month of May as the Hepatitis Awareness Month every year majorly aiming to spread awareness about hepatitis infections and motivate people, particularly those at high risk, to undertake pre-diagnosis. Similarly, the Canadian Liver Foundation and the American Liver Foundation celebrate the month of October as the Liver Awareness Month in Canada and the US, respectively. Such awareness programs lead to more people opting for treatment, thereby increasing drug consumption and market revenue.”

According to the report, one of the major drivers for this market is Increase in alcohol-related liver disease. Alcohol consumption has become quite common. According to NIH, in 2015, 86.4% of people of age 18 years and above admitted that they drank alcohol at some point of their life. Drinking alcohol may not always lead to health issues. The problem starts with alcohol abuse or heavy intake of alcohol for a longer period. Liver cells are directly associated with alcohol consumption. One of the prime functions of the liver is to remove toxins and impurities such as alcohol from the blood.

Further, the report states that one of the major factors hindering the growth of this market is Side-effects of liver disease treatment drugs. Serious side-effects of liver disease treatment drugs reduce patient compliance and might also result in patient dropouts, which, in turn, decreases the demand for the drugs, thus reducing its sales. Currently, liver disease treatment drugs such as hepatitis drugs are approved for administration in combination with other drugs such as PEG-IFN and ribavirin.

PEG-IFN and ribavirin are associated with their own side-effects and thereby add to the adverse effects when used as a combination therapy. Similarly, the combination therapy of Sovaldi and ribavirin is associated with headache and fatigue. The combination therapy of Sovaldi, ribavirin, and PEG-IFN is associated with side-effects such as insomnia, fatigue, anemia, and headache. IFN-based drugs are administered via injections, hence, inclusion of IFNs also increases the propensity of injection site reactions. Ribavirin is also associated with fetal death and birth defects.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
  • ristol-Myers Squibb
  • Johnson and Johnson
  • Novartis
  • Salix Pharmaceuticals
  • Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll